BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 126095)

  • 21. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.
    Gurewich V; Pannell R; Louie S; Kelley P; Suddith RL; Greenlee R
    J Clin Invest; 1984 Jun; 73(6):1731-9. PubMed ID: 6725557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR; Miletich JP; Sobel BE; Jaffe AS
    Thromb Res; 1988 Jun; 50(5):707-17. PubMed ID: 3137687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal fibrinolysis: evidence for the efficiency of the tissue-type plasminogen activator.
    Moore KL; Bang NU; Broadie TA; Mattler LE; Marks CA
    J Lab Clin Med; 1983 Jun; 101(6):921-9. PubMed ID: 6682880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
    Pannell R; Gurewich V
    Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
    Ries M; Zenker M; Gaffney PJ
    Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.
    Harpel PC; Chang TS; Verderber E
    J Biol Chem; 1985 Apr; 260(7):4432-40. PubMed ID: 3156857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Mechanism of thrombolytic enzymes].
    Matsuo O
    Rinsho Ketsueki; 1993 Apr; 34(4):395-402. PubMed ID: 8510325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN; Kizim AI
    Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of Val442-plasminogen (mini-plasminogen) by urokinase, streptokinase and tissue plasminogen activator.
    Takada A; Takada Y; Sugawara Y
    Thromb Res; 1988 Jan; 49(2):253-63. PubMed ID: 3129817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative evaluation of fibrinogen and fibrin hydrolysis with plasmin].
    Kastrikina TF; Taran LD; Makogonenko EM; Kudinov SA
    Ukr Biokhim Zh (1978); 1983; 55(3):266-70. PubMed ID: 6223426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro comparison of fibrinolytic activity of plasminogen activators using a thrombelastographic method: in vivo evaluation of the B-chain-streptokinase complex in the dog model using pre-titered doses.
    Summaria L; Sandesara J; Yang G; Vagher JP; Caprini JA
    Thromb Haemost; 1986 Aug; 56(1):71-9. PubMed ID: 2946093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A rapid and sensitive 125I-fibrin solid-phase fibrinolytic assay for plasmin.
    Moroz LA; Gilmore NJ
    Blood; 1975 Oct; 46(4):543-53. PubMed ID: 126094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of the fibrinolytic system.
    Robison AK; Collen D
    Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards.
    Brommer EJ
    Thromb Res; 1984 Apr; 34(2):109-15. PubMed ID: 6539513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Streptokinase-dependent potentiating factor (SK-potentiator) for plasminogen activation from human plasma: its identification as a fibrinogen degradation product.
    Hishikawa-Itoh Y; Sugie I; Kato H; Iwanaga S
    J Biochem; 1982 Oct; 92(4):1129-40. PubMed ID: 6890955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.